Peramprizumab

N/A

Report date: 2022/02/09 16:38:28

Base Information

Drug NamePeramprizumab
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-PD-1
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNasopharyngeal Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSun Yat-Sen University
China Registration ClassN/A

Develop Information

Active CompaniesSun Yat-Sen University
Inactive CompaniesN/A
Active IndicationsNasopharyngeal Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A